UBS analyst Timothy Arcuri lowered the firm’s price target on Teradyne (TER) to $130 from $155 and keeps a Buy rating on the shares. Near-term weakness obscured Teradyne’s positive long-term outlook at its analyst day event, the analyst tells investors in a research note. The firm sees weakness as an attractive opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TER:
- Teradyne price target lowered to $110 from $125 at Stifel
- Teradyne price target lowered to $140 from $150 at KeyBanc
- Teradyne price target lowered to $85 from $100 at BofA
- Teradyne Positioned for Growth Amid Industry Trends and Strategic Acquisitions
- Teradyne’s Revised Guidance and Trade Uncertainties Prompt Sell Rating by Analyst Shane Brett
Questions or Comments about the article? Write to editor@tipranks.com